| Literature DB >> 28337491 |
R W Omange1, A O Ocholla2, A O Kwallah3, S N Kageha3, J Mwangi3, R K Cherutich4, Odeny T A3, T Nzomo5, S Angwenyi6, P Yonga7, F Kariuki8, M Kyalo9, P C Mutai10, F Nindo11, E M Songok12.
Abstract
BACKGROUND: The Ebola virus disease outbreak of 2014 was the largest, longest and most devastating in the history of the disease. It demonstrated the social and economic impact an emerging infectious disease can have in a globalized world. Health systems in affected countries were stretched to the point of near collapse, while social relations and traditional practices were negatively impacted. Heads of African research institutions, African government representatives, leaders of global pharmaceutical companies, global infectious disease experts and close to 100 young African researchers from 25 countries; Assembled in Geneva on 19 and 20th October 2015, for the inaugural UNESCO-Merck Africa Summit sponsored by the United Nations Educational, Science and Culture Organization and Merck KGA. GOAL OF SUMMIT: The primary goal of the summit was to develop strategies to increase health research capacity in Africa, with special focus on Ebola and enhancing pandemic preparation for emerging infectious diseases. The summit was also provide a forum to showcase the research taking place in Africa, and provided platform for African researchers to network. Some of the key issues discussed included; strategies for enhancing policy frameworks to promote knowledge translation, strengthening of health systems, enhancing knowledge and data sharing, and increasing innovation in Africa.Entities:
Year: 2016 PMID: 28337491 PMCID: PMC5349763 DOI: 10.4314/ajid.v11i1.4537
Source DB: PubMed Journal: Afr J Infect Dis ISSN: 2006-0165
The Conclusions of an Ebola Research and Development Summit for stakeholders from different sectors (government, industry, scientific, agencies, NGOs and civil society)
| Lessons learnt as derived from the work relating to Ebola, were: |
| • Need for new R&D funding models which would support the development of products where the market is inconsistent, unknown or unreliable. |
| • Future R&D must encompass more than just vaccines, drugs and diagnostics. |
| • Establish standards for evaluating the efficacy of targets compounds in the intra-epidemic period |
| • Need to develop broader road maps for identifying prioritizing interventions for evaluation in the setting of an ongoing outbreak. |
Pillars of Knowledge (research) translation
| RESEARCH TRANSLATION PILLARS | ||
|---|---|---|
| Research Infrastructure | Technical/Professional Competences | Enabling Research Environments |
| Strengthening R&D | Science workforce-M.Sc and PhDs | Financial support for knowledge translation |
| National research institutions | Technological transfer | Advocacy and communication |
| Intellectual property systems | ||
| Private sector R&D research facilities | Knowledge exchange | Research policies and strategies |
| Innovation and entrepreneurship promotion | ||
| Academic institutions (universities, institutes or colleges) | ||
| Science/Innovation Parks | ||
*Adapted from Dr Ahmed Hamdy’s presentation at UNESCO-MARS 2015.